Intratect

Human Normal Immunoglobulin, the active ingredient in Intratect, is an immunoglobulin presented as a sterile solution for intravenous use. It provides passive immunity by supplying pooled IgG antibodies and is used to treat patients with primary immunodeficiency, secondary immunodeficiency, and certain autoimmune disorders.

GNH USA supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company ensures quality manufacturing and regulatory compliance for global distribution.

Intratect is an intravenous immunoglobulin used to replace deficient antibodies and modulate immune responses in several clinical conditions.

- Primary Immunodeficiency: reduces the frequency and severity of infections by supplying functional IgG. - Secondary Immunodeficiency (e.g., post‑chemotherapy): supports immune recovery and helps prevent opportunistic infections. - Immune Thrombocytopenic Purpura (ITP): raises platelet counts and reduces bleeding risk. - Kawasaki Disease: decreases coronary artery inflammation and aneurysm formation.

Adverse reactions may occur with intravenous immunoglobulin therapy. Patients should be monitored for any signs of intolerance.

Common Side Effects: - Headache: mild to moderate, often transient. - Fever or chills: usually within the first infusion. - Fatigue or malaise: resolves after infusion. - Nausea or vomiting: may accompany infusion. - Infusion‑related reactions: flushing, erythema, or mild hypotension. - Muscle aches: transient discomfort.

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction: requires immediate medical attention. - Thromboembolic events: stroke, myocardial infarction, or deep‑vein thrombosis. - Acute renal failure: especially in patients with pre‑existing kidney disease. - Aseptic meningitis: severe headache, neck stiffness, photophobia. - Hemolysis: hemoglobin drop, especially with high‑dose regimens. - Severe thrombocytopenia: unexpected drop in platelet count.

Intratect requires careful patient assessment and monitoring to minimize risks.

- Renal function assessment: evaluate baseline creatinine and adjust infusion in renal impairment. - Thrombotic risk monitoring: assess history of clotting disorders and consider prophylactic measures. - IgA deficiency screening: patients with anti‑IgA antibodies may develop severe reactions. - Allergy history review: identify prior hypersensitivity to blood products. - Infusion rate adjustment: start slowly in patients with cardiovascular disease or fluid overload risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intratect can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection; avoid concurrent administration. - Warfarin or other anticoagulants: IVIG can affect INR and increase bleeding risk. - High‑dose aspirin or NSAIDs: may heighten risk of renal dysfunction. - Rituximab or other B‑cell depleting agents: can reduce IVIG efficacy. - Immunosuppressive chemotherapy: may require dose adjustments.

Moderate Interactions (Monitor Closely): - Antibiotics (e.g., penicillins): increased risk of rash. - Corticosteroids: combined immunosuppression may raise infection risk. - Diuretics: monitor fluid balance and renal function. - ACE inhibitors: watch for additive hypotensive effects. - Vaccines (inactivated): efficacy may be reduced; schedule appropriately.